Eventually, AstraZeneca’s board decided to reject ... lines to justify their acts of omissions and commissions under the banner of “national interest”, the argument goes.

AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery. The companies say the ...

AstraZeneca recently reported a 1.9% decline in its share price over the last week. This movement coincides with the broader market's downturn, which saw a 1.1% drop amid ongoing concerns about ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology.

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

April 22 (Reuters) - AstraZeneca (AZN.L), opens new tab has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and Manufacturers of America ...

AstraZeneca has rejoined PhRMA as it expands its “presence in the United States with significant investments in research, development and manufacturing,” Pascal Soriot, AZ’s CEO, said in a ...

The CEO of FTSE 100 giant Astrazeneca has spoken out. (Photo by Christopher Furlong/Getty Images) Europe is putting its “ability to protect the health of its own people at risk” by not ...

LONDON, April 23 (Reuters) - AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that just like Europe has stepped up its defence spending it now must do the same and invest more ...

Soliris (eculizumab) was first approved for paroxysmal nocturnal hemoglobinuria (PNH) in 2007 under Alexion, which later became AstraZeneca’s rare disease unit after its $39 billion buyout in 2020.